The edition · Dermatology
Stopping eczema treatment in remission: orals relapse early, biologics hold
A network meta-analysis on tapering systemic atopic dermatitis therapy, a phase 2 signal for a targeted cutaneous lupus drug, a staphylococcal vaccine that failed, and a transplant skin-cancer triage that works.
The edition in brief
A network meta-analysis of 55 studies on stepping down systemic atopic dermatitis treatment after remission found early relapse when oral agents were stopped, while biologic responses were largely sustained after withdrawal or interval extension, with lebrikizumab performing best in the network. In the phase 2 part of AMETHYST, the anti-BDCA2 antibody litifilimab gave clear or almost clear skin in 14.7% of patients with cutaneous lupus versus 2.9% on placebo at week 16. A five-antigen Staphylococcus aureus vaccine raised strong antibody responses but did not reduce recurrent skin and soft tissue infections and stopped for futility. A Swedish cohort of 395 organ transplant recipients showed a simple low, intermediate and high risk grouping separated skin cancer risk sharply, with hazards about 6 and 12 times higher in the upper groups. The pearl covers recurrent boils.
Litifilimab improved cutaneous lupus in a phase 2 trial
Litifilimab shows promise for cutaneous lupus, but at phase 2 it is a reason to watch the phase 3 results, not to change treatment.
A staphylococcal vaccine raised antibodies but did not prevent recurrent skin infection
Prevention of recurrent staphylococcal skin infection still depends on drainage, hygiene and decolonisation, not vaccination.
A three-tier triage separated skin cancer risk in transplant recipients
Consider risk-tiered follow-up for transplant recipients so the busiest clinic time goes to those most likely to develop invasive skin cancer.
Recurrent boils: drain, swab, and check the household
For recurrent boils, swab and think household-wide before reaching for another antibiotic course.
In atopic dermatitis remission, oral agents relapse early when stopped; biologics hold
When stepping down atopic dermatitis treatment in remission, consider extending a biologic's interval first and expect quicker relapse if an oral agent is stopped.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for dermatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free